text_1: 与 化疗 相比 , gilteritinib 显著 改善 了 中位 OS ( 9.3 个 月 vs . 5.6 个 月 ) 和 CRR ( 34.0% vs . 15.3% ) ; gilteritinib 也 改善 了 1 年 生存率 ( 37.1% vs . 16.7% ) .
  
text_2: median OS was significantly improved with gilteritinib versus chemotherapy ( 9.3 vs. 5.6 months ) , as was CRR ( 34.0 % vs. 15.3 % ) ; survival at 1 year was also improved with gilteritinib ( 37.1 % v. 16.7 % ) .
  